Bayer steps up with $1.55B deal to take a lead role in commercializing Loxo’s cancer drugs
Bayer is buying into the closely-watched pivotal cancer program underway at Loxo Oncology $LOXO. And they are paying big to partner on Loxo’s pipeline of genetically defined cancer therapies.
Bagging commercialization rights on larotrectinib, its follow-up drug LOXO-195 and the whole pipeline at Loxo, Bayer is handing over a $400 million upfront, $450 million in milestones for the development and first sale of larotrectinib, with another $200 million on the table for LOXO-195. There’s also $500 million on the books for commercial goals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.